Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

I agree, but I doubt Remdesivir will be part of the protocol. My guess is we will see a step wise protocol in the patients with significant but early pulmonary involvement.Hopefully Brilacidin will prove to be the antiviral of choice with Dexamethasone and anti coagulants added as the disease progresses.

So far the many other anti-inflammatories and antivirals seem to be only weakly effective, but they may prove to be effective in subsets of the very ill patients. eg leronlimab, tocilizumab etc

Merck and Oncoimmune's GVH drug, CD24Fc, had impressive results , but the FDA is requiring additional testing. Dexamethasone is going to be difficult to replace.

The treatment regimen needs an effective antiviral. A combination of antivirals with different complementary mechanisms of action may be necessary, but Brilacidin is the only virucidal, anti-capsid drug being studied and it may have 2 other antiviral MOA's plus the anti-inflammatory and antibiotic properties.

We should know more soon as the Phase 2 Brilacidin study is reported.

https://www.fiercebiotech.com/biotech/fda-tells-merck-told-to-show-more-data-for-its-oncoimmune-covid-drug-as-eua-pushed-back

GLTA, Farrell